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Doxycycline is the treatment of choice for canine monocytic ehrlichiosis (CME), a well-characterized disease
and valuable model for tick-borne zoonoses. Conflicting reports of clearance of Ehrlichia canis after treatment
with doxycycline suggested that the disease phase during which treatment is initiated influences outcomes of
these treatments. The purpose of this study was to evaluate the efficacy of a 28-day doxycycline regimen for
clearance of experimental E. canis infections from dogs treated during three phases of the disease. Ten dogs
were inoculated with blood from E. canis carriers and treated with doxycycline during acute, subclinical, or
chronic phases of CME. Daily rectal temperatures and semiweekly blood samples were monitored from each
dog, and Rhipicephalus sanguineus ticks were acquisition fed on each dog for xenodiagnosis. Blood collected
from dogs treated during acute or subclinical CME became PCR negative for E. canis as clinical parameters
improved, but blood samples collected from dogs treated during chronic CME remained intermittently PCR
positive. R. sanguineus ticks fed on dogs after doxycycline treatments became PCR positive for E. canis,
regardless of when treatment was initiated. However, fewer ticks became PCR positive after feeding on two
persistently infected dogs treated with doxycycline followed by rifampin, suggesting that antibiotic therapy can
reduce tick acquisition of E. canis.
Tick-borne diseases attributable to the rickettsial family
Anaplasmataceae have been subject to increasing interest from
veterinary and public health perspectives. Several members of
this group naturally infect dogs and have emerged as tick-
borne zoonotic pathogens over recent decades (41, 59). Exper-
imental studies of these diseases and their etiologic agents can
be challenging, but Ehrlichia canis, the primary etiologic agent
of canine monocytic ehrlichiosis (CME), offers a relatively
unique opportunity to study interactions between a monocyto-
tropic member of the family Anaplasmataceae and its inverte-
brate and vertebrate hosts (49).
CME canis is divided into acute, subclinical, and chronic
phases, which were primarily defined through experimental
infections of purpose-bred dogs that were infected by needle
inoculation with E. canis-infected blood (7, 8, 14, 18, 26). The
acute phase of experimental CME begins approximately 10
days postinoculation (dpi) and involves leukopenia, thrombo-
cytopenia, fever, depression, and anorexia. Notably, reports of
experimental infection with E. canis document that dogs pre-
sented signs of severe acute CME when they were inoculated
with carrier blood (8, 20, 23, 24, 42, 57) while other investiga-
tors reported less severe disease when dogs were inoculated
with E. canis-infected cell cultures (17, 20, 28, 30, 40). Clinical
signs subside approximately 20 to 30 dpi, which is usually
followed by a subclinical phase that can last from months to
years. Although there are minimal clinical signs during the
subclinical disease phase, hematologic signs such as leukope-
nia, anemia, and thrombocytopenia can still occur, with mild
thrombocytopenia as the most consistent finding under exper-
imental conditions (57). Chronic CME is the third phase,
which may be mild to severe, with recurrent clinical and he-
matologic signs that include pancytopenia, hemorrhage, mono-
cytosis, lymphocytosis, and weight loss (8, 10, 16, 18, 38, 45).
Tetracyclines are the antibiotics of choice for treatment of
numerous tick-borne bacterial diseases, including those asso-
ciated with rickettsial pathogens (41, 59). Similarly, oral doxy-
cycline is commonly used for treatment of CME. Although
doxycycline effectively ameliorates clinical CME, there are
conflicting reports of the efficacy of the same treatment regi-
mens for clearance of E. canis infection from these hosts. Some
reports suggest persistence of infection following 7- to 85-day
doxycycline regimens of naturally and experimentally infected
dogs during postacute phases of CME (1, 23, 29, 58) while
other reports indicate clearance of E. canis after 14- to 60-day
doxycycline treatments of dogs during acute CME (4, 22). A
28-day course of oral doxycycline is the currently recom-
mended protocol issued by a consensus statement of the Amer-
ican College of Veterinary Internal Medicine for treatment of
CME (39).
We have observed similarly discrepant results with regard to
persistence of E. canis infection in dogs following doxycycline
regimens. E. canis infections were detected in peripheral blood
and in Rhipicephalus sanguineus ticks acquisition fed as nymphs
after a 14-day doxycycline regimen from dogs that were in-
fected by tick transmission that resulted in mild acute-phase
CME (43). Conversely, E. canis infections were not detected in
peripheral blood after a 28-day doxycycline regimen from dogs
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that were infected by intravenous inoculation of carrier blood
that resulted in severe acute-phase CME (42). Differences in
experimental designs and results among these and the afore-
mentioned studies collectively suggest that E. canis infections
might be less likely to be cleared by doxycycline when they are
transmitted by ticks, after mild acute CME, or as CME
progresses through different phases. To test the last hypothesis,
dogs were intravenously inoculated with E. canis carrier blood,
to ensure severe acute-phase CME, and treated during three
different clinical phases of CME. E. canis infections were mon-
itored by PCR assays of host blood and ticks fed on each host
after treatment.
MATERIALS AND METHODS
Experimental dogs. Ten adult purpose-bred beagle dogs were experimentally
infected with E. canis by intravenous (i.v.) inoculation of heparinized E. canis
carrier blood. Dogs BIW and BMN were each simultaneously inoculated with 10
ml of heparinized blood from dog A72, a persistently infected E. canis (Ebony
isolate) carrier (47). At 287 dpi, dogs BIW and BMN served as sources of
infectious blood for the remaining dogs used in this study. In the first trial, dogs
AFA, AMP, ACH, and AAN were each simultaneously inoculated with 5 ml of
heparinized blood from BIW. In the second trial, dogs ALK, AFW, ANR, and
BIX were each simultaneously inoculated (i.v.) with 5 ml of heparinized blood
from BMN. Doxycycline treatments were initiated (10 mg/kg of body weight
[kgbw], per os [p.o.], once a day [q.d.], for 28 days) during the acute, subclinical,
and chronic phases of CME at 16, 62, and 505 dpi, respectively (Fig. 1). To the
best of our knowledge, dog A72, a long-term E. canis carrier, had not been
exposed to doxycycline since experimental infection with E. canis via tick trans-
mission (47). Likewise, dogs BMN and BIW, which were used as donors for the
remaining dogs, were not exposed to doxycycline prior to the treatments used in
the current study. Dogs were monitored for 2 weeks after receiving their final
doses of antibiotic. Daily rectal temperatures were recorded for each dog, and
semiweekly blood samples were collected for complete blood counts (CBCs) and
PCR assays as described below. Blood samples used for hematological testing
were collected in evacuated glass tubes containing EDTA (Kendall Monoject
311149), and CBC profiles were measured by the clinical pathology laboratory at
the University of Missouri College of Veterinary Medicine with an Abbott Cell
Dyn 3500 (Abbot Laboratories, Abbot Park, IL). Blood samples were collected
for PCR assays in heparinized evacuated glass tubes (Vacutainer, item 366480;
BD). Dogs used for this study were cared for in accordance with a protocol on
file with the University of Missouri Columbia Animal Care and Use Committee.
Xenodiagnosis. Adult R. sanguineus male ticks were purchased from the Okla-
homa State University Medical Entomology Laboratory. Ticks were placed into
orthopedic stockinettes adhered to the surface of each dog and allowed to feed
for 10 days, as previously described elsewhere (6). Heparinized blood was col-
lected from dogs treated with doxycycline during the acute (2 ml per dog),
subclinical (2 ml per dog), or chronic (5 ml per dog) CME phase, and 8 to 10 ml
of pooled blood was inoculated into naïve dogs as an additional test for persistent
infections in host blood.
PCR assays. Heparinized blood samples (1 ml) were centrifuged at 1,200  g
for 30 min, buffy coat layers were isolated (200 l), and DNA was extracted
with a High Pure Viral Nucleic Acid Isolation kit (Roche, Indianapolis, IN) as
previously described elsewhere (35). Two extra buffy coats were stored at 80 °C
for each sample collected as replicates in the event that PCR-positive samples
were observed after doxycycline treatment; samples were interpreted as negative
when frozen replicates tested negative by PCR. In preparation for PCR, frozen
buffy coats were overlaid with 1.5 ml of RNAlater-ICE (Ambion Inc., Austin,
TX) and stored (20°C) for 18 h. These samples were centrifuged (12,000 
g for 15 min at 4°C), and supernatants were discarded prior to DNA isolation as
described above.
Ticks were removed from dogs, grouped according to host, and stored in the
same humidity chamber for 10 days at room temperature (RT) and 95 to 100%
rH, with a 12:12-h light-dark photoperiod. Previous work has shown that anaplas-
mal pathogens incapable of infecting ticks are detectable for only 2 days after tick
removal from the host (50). Thus, these ticks remained in the humidity chamber
for 10 days to improve the likelihood of detection of E. canis in infected ticks
rather than in remnants of blood meals from the canine hosts (6). After incu-
bation to allow blood meal removal, these ticks were then incubated for another
85 h at 37°C (100% rH) prior to bisection and DNA isolation. New razor blades
were used for ticks collected from each individual dog, and these blades were
flame sterilized prior to bisection of each individual tick. Ticks collected before
and after doxycycline treatments did not occupy humidity chambers at the same
time. Tick halves were immediately placed on dry ice and stored at 80°C until
DNA was extracted with the same protocol used for blood.
A p30-based PCR assay was used to test for the presence of E. canis DNA as
previously described elsewhere, with some modifications (6, 35, 42, 43, 47).
Briefly, 25-l reaction mixtures were prepared with 2% dimethyl sulfoxide
(DMSO), 2.0 mM MgCl2, 200 M of each deoxynucleoside triphosphate
(dNTP), 0.3 M (each) of primers ECA30-384S (ATAAACACGCTGACTTT
ACTGTTCC) and ECA30-583A (GTGATGAGATAGAGCGCAGTACC), and
0.03 U/l of Platinum Taq polymerase (Invitrogen, Carlsbad, CA). Samples were
incubated at 94°C for 2 min, followed by 75 cycles at 94, 65, and 72°C for 30 s
each, with a final extension for 7 min at 72°C. Positive controls consisted of 10 pg
of DNA extracted from E. canis-infected DH82 cell cultures that were prepared
as previously described (6, 35) while negative controls consisted of preinocula-
tion canine blood and unexposed ticks. No-template controls served as tests for
contamination for every assay. Every sample was assayed a minimum of two
times, followed by a third assay of samples with discrepant results between the
two trials. Amplicons of representative samples were excised from agarose gels,
extracted with a Wizard SV Gel and PCR Clean Up System (Promega, Madison,
WI), and submitted to the University of Missouri DNA Core Facility for se-
quencing of both DNA strands. Amplicon sequences were compared via multiple
sequence alignment with CodonCode Aligner (CodonCode Corporation, Ded-
ham, MA).
RESULTS
Efficacy of doxycycline for treatment of experimental CME.
Reports of clearance of E. canis infections from experimentally
infected hosts usually involved (i) needle inoculation (i.v.) with
infected host cells and (ii) treatment during the acute phase of
clinical CME (4, 12, 22). Thus, dogs used in the current study
were inoculated with carrier blood (i.v.) to consistently induce
overt signs of clinical CME including fever and pancytopenia
that began 14 to 16 dpi (Fig. 2).
(i) Acute phase. Treatment regimens for dogs AFA, AFW,
ALK, and AMP were initiated approximately 24 h after clinical
FIG. 1. Induction of experimental ehrlichiosis. Clinical CME was
induced in dogs by inoculation of E. canis carrier blood. Dogs BIW and
BMN were each simultaneously inoculated with 10 ml of heparinized
blood from dog A72, and blood collected from dog BIW or BMN (287
dpi) was inoculated into dogs AFA, AMP, ACH, and AAN or into
dogs ALK, AFW, ANR, and BIX, respectively. Doxycycline treatments
were initiated 16 dpi for dogs AFA, AFW, ALK, and AMP, at 62 dpi
for dogs ACH, AAN, ANR, and BIX, and at 505 dpi for dogs BIW
and BMN.
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and hematological signs of CME became apparent (16 dpi).
Clinical signs of CME abated among all four dogs soon after
treatment was initiated, and CBC parameters continually im-
proved during and after the treatment period (Fig. 2). Rectal
temperatures of this group increased from a preinoculation
baseline of 38.8  0.5°C (mean  standard deviation [SD]) to
a peak of 40.3  0.2°C at 15 dpi, which recovered to 37.7 
0.3°C by 32 dpi, 16 days posttreatment initiation (dpti). Platelet
counts of this group dropped from a baseline of 2.76  105 
0.65 105 to a nadir of 3.4  104  3.0  104 at 16 dpi, which
recovered to 2.62 105  1.23  105 platelets per l by 38 dpi
(22 dpti). Similarly, leukocyte counts of this group dropped
from a baseline of 8.30  103  1.70  103 to a nadir of 3.30 
103  0.80  103 at 17 dpi, which recovered to 1.033  104 
0.291  104 leukocytes per l by 28 dpi (12 dpti). Hematocrit
values dropped from a baseline of 44.7  3.8% to a nadir of
39.4  4.0% at 31 dpi, which recovered to 45.0  3.8% by 49
dpi (33 dpti).
(ii) Subclinical phase. Treatment regimens for dogs AAN,
ACH, ANR, and BIX were initiated at 62 dpi. Body temper-
atures of all four dogs returned to the normal range by 61 dpi,
thus prior to initiation of treatment, and CBC parameters
began to recover after the initial nadir at approximately 21 dpi
(Fig. 2). Rectal temperatures of this group rose from a prein-
oculation baseline of 38.7  0.4°C to a peak of 40.0  0.6°C at
15 dpi, which recovered to 38.5  0.3°C at initiation of doxy-
cycline therapy (62 dpi) and to 37.9  0.2°C by 67 dpi. Platelet
counts of this group dropped from a baseline of 3.04  105 
0.48  105 to a nadir of 1.5  104  1.1  104 at 21 dpi, which
recovered to 1.0  105  0.6  105 at 62 dpi and to 3.00 
105  0.70  105 platelets per l by 84 dpi (22 dpti). Leukocyte
counts of this group dropped from a baseline of 9.40  103 
2.50  103 to a nadir of 5.50  103  0.39  103 at 17 dpi,
which recovered to 7.2  103  0.6  103 at 62 dpi and to
8.80  103  1.86  103 leukocytes per l by 66 dpi (4 dpti).
Hematocrit values dropped from a baseline of 45.1  4.6% to
a nadir of 30.4  2.7% at 45 dpi, which recovered to 36.4 
2.4% at 62 dpi and 45.6  1.4% by 87 dpi (25 dpti).
(iii) Chronic phase. Treatment regimens for dogs BIW and
BMN were initiated at 505 dpi. Both dogs exhibited signs of
severe CME during the acute phase of the disease (Fig. 2).
Rectal temperatures of this group changed from a preinocu-
lation baseline of 38.7  0.3°C to a peak of 40.2  0.5°C at 19
dpi, which averaged 37.3  0.6°C at 445 dpi (60 days before
treatment) and were 39.3  0.7°C at the time of treatment (505
dpi). Platelet counts dropped from a baseline of 2.97  105 
0.79  105 to a nadir of 7.0  103  6.0  103 at 48 dpi, which
recovered to 1.92  105  0.64  105 platelets per l at 503
dpi, 2 days prior to initiation of treatment, and further recov-
ered to 2.43  105  0.11  105 platelets per l by 517 dpi (12
dpti). Leukocyte counts dropped from a baseline of 9.70 
103  2.40  103 to a nadir of 3.27  103  1.36  103 at 44
dpi, which recovered to 1.059  104  0.680  104 leukocytes
per l by 62 dpi (443 days before treatment) and were 4.8 
105  2.1  105 leukocytes per l at 503 dpi. Hematocrit values
dropped from a baseline of 43.3  2.4% to a nadir of 27.1 
2.3% at 44 dpi, which recovered to 45.1  3.2 by 503 dpi, 2 days
prior to initiation of treatment, and further recovered to
50.2  3.7% by 520 dpi (15 dpti).
Clearance of E. canis during different phases of CME. (i)
Acute phase. Previous reports of clearance of E. canis from
experimentally infected hosts usually involved initiation of
treatment during the acute phase of CME (4, 12, 22). Thus, the
working hypothesis for this experiment was that administration
of a 28-day doxycycline regimen during the acute phase of
CME would eliminate E. canis infections. To test this hypoth-
esis, peripheral blood was collected before, during, and after
doxycycline treatment of dogs AFA, AFW, ALK, and AMP
and assayed for the presence of E. canis. Xenodiagnosis was
also performed by allowing adult male R. sanguineus ticks to
acquisition feed for 10 days on each dog, starting 11 days after
the final doxycycline treatment (i.e., 57 to 68 dpi). Cohorts of
FIG. 2. Clinical responses to doxycycline treatment by dogs treated
during different phases of ehrlichiosis. Dogs were inoculated with
blood from a persistently infected E. canis carrier on day 0, and
treatment with doxycycline was initiated during the acute (16 dpi),
subclinical (62 dpi), or chronic (505 dpi) phase of ehrlichiosis. Each
panel (top to bottom), respectively, illustrates rectal temperature,
platelet, white blood cell, or hematocrit values. Dotted, dashed, or
solid lines represent dogs treated during the acute, subclinical, or
chronic phase, respectively. Open, light gray, and dark gray rectangles
represent treatment periods during the acute, subclinical, and chronic
phases, respectively.
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these ticks were fed on a naïve dog to serve as controls. In
addition, 2 ml of blood was collected from each dog at 114 dpi
(98 dpti), pooled, and inoculated (i.v.) into a naïve dog (AVS)
as a test of infectivity.
E. canis was not detected in blood prior to inoculation but
was detected in all four dogs by 7 dpi. Blood samples from
these dogs continued to test positive up to 24 to 28 dpi (8 to 12
dpti), and peripheral blood from these dogs remained PCR
negative throughout the remainder of the study except for two
samples collected from dogs AFW (38 dpi) and AMP (51 dpi)
(Fig. 3A). Frozen replicates of these samples tested PCR neg-
ative. However, 2 to 7 of 10 R. sanguineus male ticks fed on
these dogs tested PCR positive while both unfed and fed co-
horts of these ticks were PCR negative (Fig. 3B).
Dog AVS, which was inoculated with pooled blood from this
group, did not exhibit overt clinical signs of CME although the
rectal temperature for dog AVS did rise from a preinoculation
baseline of 38.4  0.6°C to a peak of 39.9°C at 5 dpi. Platelet
counts for this dog did not decrease following inoculation but
instead rose from a baseline of 2.23  105  0.44  105 to
2.43  105 at 28 dpi while leukocyte counts dropped from a
baseline of 8.40  103  0.40  103 to a nadir of 7.16  103 at
35 dpi, and hematocrit values dropped from a baseline of
47.5  2.0% to a nadir of 43.3% at 39 dpi. Overall these
parameters changed 4, 9, 15, and 9% from baseline values
for rectal temperature, platelet count, leukocyte count, and
hematocrit, respectively. However, E. canis was detected in
peripheral blood collected from this dog at 14, 28, and 31 dpi
(Fig. 3C), and the frozen backup samples for 14 and 28 dpi also
tested positive by PCR.
(ii) Subclinical phase. Several reports suggested that E. ca-
nis infections can persist in dogs treated with doxycycline dur-
ing postacute phases of CME (23, 29, 43, 58). Thus, the work-
ing hypothesis for this experiment was that the initiation of a
28-day doxycycline regimen during the subclinical phase of
experimental CME would result in less efficacious elimination
of E. canis infections than treatment during the acute phase of
the disease. The 28-day doxycycline treatments were initiated
for dogs ACH, AAN, ANR, and BIX at 62 dpi. Xenodiagnosis
was also performed with acquisition-fed R. sanguineus both
before and after doxycycline treatment at 22 and 123 dpi,
respectively. Blood (2 ml) was collected from each dog at 135
dpi (73 dpti), pooled, and inoculated (i.v.) into dog AHS.
E. canis was not detected in blood prior to inoculation but
was detected among this group as early as 3 dpi, and these dogs
remained consistently PCR positive throughout the acute and
subclinical phases of CME. However, these infections were not
detected in peripheral blood within 7 dpti (Fig. 4A), except for
three samples from dogs AAN (87 dpi) and ACH (98 and 101
dpi). Frozen backup buffy coats of these samples tested PCR
negative. However, 2 to 4 of 10 R. sanguineus male ticks
tested positive by PCR when fed prior to treatment while 1
to 5 of 10 ticks tested PCR-positive after doxycycline treat-
ment (Fig. 4B).
Dog AHS, which was inoculated with pooled blood from this
group, did not become PCR positive or exhibit signs of disease
attributable to E. canis (Fig. 4C). Rectal temperatures for dog
AHS rose from a preinoculation baseline of 38.3  0.5°C to a
peak of 39.4°C at 7 dpi. Platelet counts for this dog did not
decrease following inoculation and instead rose from a base-
line of 2.60  105  0.13  105 to 2.73  105 at 11 dpi.
Leukocyte counts for AHS dropped from a baseline of 6.50 
103  0.30  103 to a nadir of 5.95  103 at 32 dpi. Hematocrit
values dropped from a baseline of 45.4  1.7% to a nadir of
40.1% at 35 dpi. Overall, these parameters changed 5, 8, 12,
and 3% from baseline values for rectal temperature, platelet
count, leukocyte count, and hematocrit, respectively.
(iii) Chronic phase. In previous work, infections were
cleared from peripheral blood of dogs treated during subclin-
ical CME if treatment was initiated while values of CBC pa-
rameters were low (16, 42). Conversely, infections persisted
after doxycycline therapy of dogs with values of clinical and
hematological parameters that were closer to the normal range
(43, 58), and similar results were observed for naturally in-
fected dogs with higher CBC values (1, 5, 58). Therefore, the
working hypothesis for this experiment was that persistent E.
canis infections in dogs with CBC values in the normal range
are more resistant to clearance by doxycycline therapy. Two
dogs, BIW and BMN, were treated with doxycycline from 505
to 533 dpi. R. sanguineus ticks were acquisition fed on these
dogs both before and after doxycycline treatment at 434 and
549 dpi, respectively. Additionally, 5 ml of blood was collected
from each dog at 629 dpi (96 dpti), pooled, and inoculated
(i.v.) into dog BJW. Dogs BMN and BIW were also treated
FIG. 3. Detection of E. canis in dogs treated during acute CME.
(A) PCR assays of buffy coats collected semiweekly throughout the
experiment. The bar at the top of this panel represents the treatment
period from 16 to 44 dpi. (B) PCR assays of adult male R. sanguineus
ticks fed on dogs AFA, AFW, ALK, and AMP at 13 days after the end
of doxycycline treatment (57 dpi). Unfed male R. sanguineus ticks and
cohorts fed on a naïve dog served as controls. Lanes 1 to 10 represent
individual tick halves. (C) PCR assay of buffy coats from dog AVS
which was inoculated with blood pooled from dogs AFA, AFW, ALK,
and AMP after doxycycline treatment (114 dpi). All samples were
tested with a single-step E. canis-specific p30-based PCR assay. Sam-
ples resulting in a 200-bp amplicon (arrowhead) were considered PCR
positive. Asterisks denote samples with a frozen replicate that tested
PCR negative. For each panel, no-template controls (N) served as tests
for contamination, DNA (10 pg) extracted from E. canis-infected
DH82 cells served as positive control (), and lanes labeled 0 to 66 or
2 to 42 indicate dpi. The molecular size standard (M) was a 100-bp
ladder.
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with rifampin (15 mg/kgbw, p.o., twice a day [b.i.d.]) from 701
to 708 dpi, which was followed by R. sanguineus acquisition
feeding at 715 dpi.
E. canis was not detected in blood prior to inoculation but
was consistently detected in peripheral blood of both dogs
from 9 dpi until initiation of antibiotic treatment. Although
clinical signs of CME were no longer manifest prior to treat-
ment, both dogs were still PCR positive when treatment was
initiated (Fig. 5A). E. canis was intermittently detected in
peripheral blood of BMN and BIW during and after doxycy-
cline treatments. Frozen backups of these samples also tested
positive by PCR. Notably, 5 and 8 of 10 ticks fed on dogs BMN
and BIW, respectively, tested PCR positive prior to doxycy-
cline treatment while 7 and 9 of 10 ticks tested PCR positive
when fed on the same dogs after doxycycline treatments (Fig.
5B). However, only 1 of 10 ticks fed on BMN and none of the
10 ticks fed on BIW tested PCR positive for E. canis after these
dogs were treated with rifampin.
Dog BJW, which was inoculated with pooled blood from
BMN and BIW after doxycycline treatment, did not exhibit
signs of disease. Rectal temperatures for dog BJW rose from a
preinoculation baseline of 37.9  0.3°C to a peak of 38.4°C at
17 dpi. Interestingly, platelet counts for BJW decreased from a
baseline of 3.45  105  0.45  105 to a nadir of 2.29  104 at
31 dpi. Platelet aggregation was not observed in the corre-
sponding blood smear. However, this drop in platelets was
seen in only a single sample, with the next lowest value of
3.09  105. Leukocyte counts for dog BJW dropped from a
baseline of 1.06  104  0.08  104 to a nadir of 8.70  103 at
10 dpi. Hematocrit values dropped from a baseline of 50.6 
3.4% to a nadir of 45.1% at 10 dpi. Overall these parameters
changed 1, 93, 18, and 11% from baseline values for
rectal temperature, platelet count, leukocyte count, and he-
matocrit, respectively. Dog BJW tested PCR positive once at
10 dpi (Fig. 5C), which corresponded with the nadirs in leu-
kocyte and hematocrit values for this dog, and this result was
confirmed when the 10-dpi frozen backup buffy coat sample
also tested PCR positive.
FIG. 4. Detection of E. canis in dogs treated during subclinical CME. (A) PCR assays of buffy coats collected semiweekly throughout the
experiment. The bar at the top of this panel represents the treatment period from 62 to 90 dpi. (B) PCR assays of adult male R. sanguineus ticks
fed on dogs AAN, BIX, ACH, and ANR before (22 dpi) and after (123 dpi) treatment. Lanes 1 to 10 represent individual ticks. (C) PCR assays
of buffy coats from dog AHS, which was inoculated with blood pooled from dogs AAN, BIX, ACH, and ANR after doxycycline treatment (129
dpi). All samples were tested with a single-step E. canis-specific p30-based PCR assay. Samples resulting in a 200-bp amplicon (arrowhead) were
considered PCR positive. Asterisks indicate samples with a frozen replicate that tested PCR negative. For each panel, no-template controls
(N) served as tests for contamination, template DNA (10 pg) extracted from E. canis-infected DH82 cells served as a positive control (), and lanes
labeled 0 to 128 or 14 to 35 indicate dpi. The molecular size standard (M) was a 100-bp ladder.
FIG. 5. Detection of E. canis in dogs treated during chronic CME.
(A) PCR assays of buffy coats collected semiweekly throughout the
experiment. The bar at the top of this panel represents the treatment
period at 505 to 533 dpi. (B) PCR assays of adult male R. sanguineus
ticks fed on dogs BMN and BIW before (434 dpi) and after (549 dpi)
doxycycline treatment and of R. sanguineus ticks fed after treatment
with rifampin (715 dpi). Lanes 1 to 10 represent individual tick halves.
(C) PCR assay of buffy coats collected weekly from dog BJW, which
was inoculated with blood pooled from both dogs after doxycycline
treatment (629 dpi). Samples were tested with a single-step E. canis-
specific p30-based PCR assay, and those with a 200-bp amplicon (ar-
rowhead) were considered PCR positive. For each panel, no-template
controls (N) served as tests for contamination, template DNA (10 pg)
extracted from E. canis-infected DH82 cells served as a positive control
(), and lanes labeled 1 to 554 or 0 to 42 indicate dpi. The molecular
size standard (M) was a 100-bp ladder.
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Amplicon sequence analysis. Representative buffy coat and
tick samples that tested PCR positive after doxycycline treat-
ments were reassayed in order to excise and sequence the
200-bp bands for comparison to the E. canis p30 target se-
quence. One amplicon generated from a tick specimen was
99% identical to the target sequence while remaining ampli-
cons were 100% identical to the target sequence (Fig. 6).
DISCUSSION
The results of this investigation confirmed the efficacy of
doxycycline for amelioration of clinical CME during the acute
phase of the disease and potentially for clearance of E. canis
from peripheral blood when dogs are treated during the acute
and subclinical phases of disease. However, these results also
indicate that E. canis can persist in clinically normal dogs, even
after an extensive doxycycline treatment regimen. These re-
sults have important implications with regard to possible re-
crudescence of ehrlichiosis due to such persistent infections
and indicate that ehrlichiosis patients should be continually
monitored even after a clinical response to antibiotic therapy.
All of the dogs used for doxycycline treatment in this investi-
gation exhibited signs of severe acute CME, and all of the
parameters measured returned to normal levels after initiation
of doxycycline treatments. To the best of our knowledge, this is
the first report of attempted xenodiagnosis following a ri-
fampin treatment regimen, and this result suggests that a treat-
ment regimen that includes rifampin could be more efficacious
for control of vector infection. However, it should be noted
that the rifampin regimen used in the current study was sub-
sequent to the doxycycline regimen. Furthermore, we have
since observed persistent E. canis infections in two dogs after
treatment with rifampin in the absence of any other antibiotic
(data not shown). Therefore, the results of the rifampin regi-
men used in this report should be interpreted with caution.
Doxycycline treatment effectively mitigated the clinical signs
associated with acute CME. Values of CBC parameters for
dogs treated during the acute phase dropped to 12.3, 39.8, and
88.1% of baseline for platelets, leukocytes, and hematocrit,
respectively, and the same respective parameters recovered to
94.9, 124.5, and 100.7% of baseline values after treatment was
initiated. Recovery from acute CME was not complete among
dogs prior to treatment at 62 dpi, until after initiation of
doxycycline treatment of these dogs. Collectively, values of
CBC parameters dropped to 5, 58.5, and 67.4% and, after
treatment was initiated, recovered to 98.7, 93.6, and 101.1% of
baseline for platelets, leukocytes, and hematocrit, respectively.
Rectal temperatures had fully recovered while hematological
values had increased but not fully recovered among dogs al-
lowed to reach the chronic phase of CME. Further recovery
was observed after initiation of treatments at 505 dpi. For this
group, platelet, leukocyte, and hematocrit values, respectively,
dropped to 2.3, 34.0, and 61.2%; recovered to 64.6, 109.3, and
104.0% of baseline; were at 36, 51, and 104% of baseline prior
to treatment (503 dpi); and reached 81.8, 68, and 113.3% of
baseline values after treatment was initiated. The lower aver-
age leukocyte value observed for this group prior to treatment
is partially due to leukocytosis observed for dog BIW at two
time points during the subclinical phase for this group, skewing
FIG. 6. Sequences of selected PCR products amplified from canine
and acarine hosts after treatment with doxycycline. Multiple sequence
alignment of amplicons from PCR-positive tick and buffy coat samples
collected after doxycycline treatment of dogs. Sequences of 200-bp bands
excised from agarose gels were aligned with the p30 target sequence (E.
canis) and primers ECA30-384S (ECF1) and the reverse complement of
ECA30-583A (ECR1). For the remaining sequences, identification codes
of the treated dogs are followed by letters indicative of amplicons from
posttreatment buffy coat (BC) samples that were confirmed with PCR-
positive frozen replicates or from ticks (T) allowed to feed on dogs after
doxycycline treatment. The sequences were aligned and compared by
using the Codoncode and Boxshade programs. Black letters surrounded
by white represent bases that are identical in each sequence of the align-
ment, and white letters in a black box indicate residues that did not match
remaining bases in the alignment.
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the average peak leukocyte value prior to initiation of doxycy-
cline treatment during the chronic phase.
Peripheral blood samples from dogs treated during the acute
or subclinical phase of CME became PCR negative and re-
mained so following treatment. However, intermittent PCR-
positive samples indicated that doxycycline treatments did not
clear E. canis from the peripheral blood of dogs treated during
chronic CME even though hematologic parameters improved
after treatments were initiated. Frozen backup samples were
assayed to confirm PCR-positive samples detected after doxy-
cycline treatments, and samples were interpreted as negative
when corresponding frozen replicates tested PCR negative.
However, it is conceivable that the templates were degraded in
the frozen replicates, resulting in reduced sensitivity of the
PCR assay. Some frozen replicates tested positive, as was the
case for samples from BMN and BIW. Furthermore, E. canis
was sporadically detected in blood collected from dogs AVS
and BJW, which were subinoculated with blood pooled from
dogs treated during acute and chronic phases of CME. Sur-
prisingly, R. sanguineus ticks tested PCR positive for E. canis
after feeding on dogs subjected to all three doxycycline treat-
ment scenarios, but only a single tick tested PCR positive after
feeding on BMN and BIW post-rifampin treatment.
The results of this investigation corroborate in some mea-
sure several studies which collectively suggest that the phase of
CME can affect the efficacy of doxycycline for clearance of E.
canis infections. For example, earlier reports indicated that
CME was resolved and that E. canis was not detected in pe-
ripheral canine blood when doxycycline therapy was initiated
during acute and subclinical phases of the disease (12, 22, 42).
Breitschwerdt et al. (4) reported successful clearance of infec-
tion from eight of eight dogs with acute experimental CME
after 14 days of treatment, while Harrus et al. (22) reported
successful clearance of infection from five of five dogs after 16
of 60 days of treatment. Conversely, other studies indicated
that E. canis infections could persist among dogs treated dur-
ing the postacute phases of CME (23, 29, 43, 58). Iqbal and
Rikihisa (29) reported reisolation of E. canis from three of five
experimentally infected dogs with subclinical CME that were
treated for 7 days. Harrus et al. (23) reported persistent E.
canis infection in one of six dogs after a 42-day doxycycline
regimen.
However, the hypothesis that E. canis infections become
more resistant to clearance by doxycycline as CME progresses
was not fully supported by the results of this study, because
infections appeared more resistant when treatments were ini-
tiated during the acute phase (16 dpi) than when treatments
were initiated during the subclinical phase (62 dpi). Notably,
the persistence of acute-phase infections during treatment was
reminiscent of an earlier study where a 14-day doxycycline
regimen failed to clear E. canis from dogs (43), indicating that
the 28-day regimen is warranted (39).
There is evidence that E. canis can persist after doxycycline
treatment of naturally infected hosts. Breitschwerdt et al. (5)
reported detection of E. canis by PCR assay in one of four dogs
tested 6 months after a 28-day doxycycline regimen prescribed
after diagnosis with ehrlichiosis attributable to E. canis. How-
ever, persistence was not distinguished from reinfection of
naturally exposed dogs in this study. Interestingly, the single
host with a detectable infection had the highest platelet count
at diagnosis (2.22  105 platelets/l), suggesting a postacute
phase of the disease, while two of the remaining three dogs,
which cleared the infections, were thrombocytopenic at initia-
tion of treatment. Wen et al. (58) screened 105 canine blood
samples from Texas and Arizona, 84% of which had been
treated with doxycycline for 1 to 24 months, suggesting that the
majority of these dogs were likely to be subclinical, and E. canis
was detected in 44% of these samples.
Several reports indicate that other Anaplasmataceae can per-
sist in hosts treated with tetracyclines. For example, Ehrlichia
chaffeensis was detected several times after doxycycline treat-
ment of 3 of 12 dogs diagnosed with ehrlichiosis (5). Notably,
this work was conducted with naturally exposed dogs in the
southeastern United States, where persistent exposure to Am-
blyomma americanum, the primary vector of E. chaffeensis,
suggested reinfection as an alternative explanation for those
results. In another study, Ehrlichia ruminantium, which is also
closely related to E. canis and E. chaffeensis, was recovered
from the blood of ruminants after treatment with oxytetracy-
cline (27), and different strains of the same pathogen were
detected by xenodiagnosis in four of five experimentally in-
fected sheep after tetracycline therapy (2). Notably, one of the
sheep described in the latter study was tested 3.5 years after
initial infection and therapy, and this sheep was subclinical at
the time of that study. Oxytetracycline (20 mg/kgbw, intramus-
cularly [i.m.]), injected three times at 3-day intervals, was re-
ported to clear natural infections of Anaplasma marginale, an
intraerythrocytic rickettsial pathogen of cattle that is closely
related to E. canis, as evidenced by failure of blood from
treated cattle to induce clinical anaplasmosis in splenecto-
mized calves (52). However, more recent studies indicate that
A. marginale infections can persist after various oxytetracycline
regimens, which was detected by both PCR assay and subin-
oculation of blood from treated hosts into susceptible calves
(11).
The results of the current study also indicate that the ability
of ticks to acquire E. canis is not always associated with de-
tectable infections within peripheral blood and that xenodiag-
nosis with ticks is the most sensitive method for detection of
such infections. Similar results were reported when Dermacen-
tor variabilis and A. americanum ticks acquired E. chaffeensis
from calves with PCR-negative blood (15). Similarly, E. rumi-
nantium was detected in adult Amblyomma variegatum ticks
acquisition fed as nymphs on experimentally infected, but
PCR-negative, sheep (2).
A satisfactory explanation for the mechanism responsible for
detection of E. canis in ticks fed on dogs with PCR-negative
blood is lacking at this time. It is conceivable that an undetect-
ably low level of the infection persists in the host blood and
that these infections are biologically amplified through repli-
cation within infected ticks. This principle underlies the long-
standing process of xenodiagnosis for detection of vector-
borne infections (36). Similar results were reported for
unrelated tick-borne parasites that replicate within the vector.
For example, Hepatozoon americanum was detected in ticks
allowed to feed on dogs with infections that are undetectable
by muscle biopsy, the most reliable method currently available
ante mortem (19). Similarly, Borrelia burgdorferi, an extracellu-
lar spirochete, was reported in Ixodes scapularis after acquisi-
tion from mice experimentally treated with doxycycline (3). In
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this case, cryptic B. burgdorferi infections were later described
in collagen layers of skin of doxycycline-treated mice (25). In
addition to low-level infections in the blood, it is also conceiv-
able that there is an undefined stage of E. canis infections that
is not detectable in peripheral blood. For example, some re-
ports suggest that Anaplasmataceae or their primary vertebrate
host cells might be closely associated with endothelium. A.
marginale and Anaplasma phagocytophilum are reportedly in-
fective for endothelial cells in vitro (37, 55, 56) as well as in vivo
(9). Both E. canis and E. chaffeensis were reported to infect a
human endothelial cell line derived from dermal microvascu-
lature in vitro, but these infections apparently did not persist
under those culture conditions, and thus further work is
needed to confirm that these monocytotropic Ehrlichia spp. are
indeed infectious to endothelium in vitro and in vivo (13).
Alternatively, monocytes infected with E. canis were observed
in close association with pulmonary endothelial cells (44), sug-
gesting that they are not limited to peripheral blood.
Additional work is needed to determine if tick infections
acquired from doxycycline-treated dogs are transmissible to
naïve hosts. Infection alone does not demonstrate pathogen
transmissibility by ticks, and there is evidence that tick-trans-
missible Anaplasmataceae are adapted to infect and pass
through at least two tick organ systems, the midgut and salivary
glands (31, 32, 48, 51, 53, 54). Furthermore, infectivity for
vertebrate hosts may not be shared by all stages of Anaplas-
mataceae that are found in their invertebrate hosts. Such was
the case for A. marginale infections described in ticks, where
infectivity of tick stages of these organisms for cattle was as-
sociated with pathogen morphology (33). Other investigators
have also reported I. scapularis acquisition of B. burgdorferi
from doxycycline-treated mice, and these spirochetes could not
be cultured and were not infectious to naïve mice (3). It re-
mains to be determined if doxycycline could similarly attenuate
members of the Rickettsiales, and this hypothesis should be
tested before bolder conclusions are drawn with regard to
acquisition and dissemination of these pathogens by ticks that
feed on hosts after antibiotic treatment.
In the present study, severe acute-phase CME was consis-
tently induced among all of the dogs tested; thus, differences
observed among these groups were not attributable to severity
of acute CME. In addition, tick acquisition feeding was utilized
for more sensitive pathogen detection and to evaluate the
efficacies of these treatment scenarios for control of vector
infection. However, although the majority of similar investiga-
tions utilized needle inoculation of anaplasmal and ehrlichial
agents for consistent induction of the associated experimental
diseases, tick transmission is the most likely infection scenario
in nature (21, 34, 46, 49). Previous reports of E. canis persis-
tence after doxycycline treatment also involved dogs that were
experimentally infected via tick transmission (43) or that were
naturally infected, presumably through tick transmission (1, 5,
58). Thus, further work is warranted to compare persistence of
E. canis among dogs experimentally infected via needle injec-
tion versus tick transmission feeding.
In conclusion, dogs were intravenously inoculated with
blood from E. canis carriers and consistently developed overt
clinical and hematologic signs of severe acute-phase CME. The
doxycycline regimen used in this study effectively ameliorated
CME among dogs treated at 16 or 62 dpi, and blood from dogs
treated during the corresponding CME phases became PCR
negative after doxycycline treatment. However, blood collected
from dogs with long-term infections intermittently tested PCR
positive during and after doxycycline treatment. Ticks were
able to acquire E. canis from all of the dogs subjected to
doxycycline treatment. Although these xenodiagnostic results
suggest that doxycycline alone may not block tick acquisition of
E. canis from dogs, regardless of when the treatment is initi-
ated, reductions in tick acquisition rates after rifampin treat-
ment suggested that a treatment regimen can be developed to
better control tick acquisition of E. canis and possibly other
rickettsial agents.
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